Prelaunch

BI, Lilly go simple in new SGLT med-ed effort

BI, Lilly go simple in new SGLT med-ed effort

By

Boehringer Ingelheim and Eli Lilly rolled out a pre-launch SGLT campaign that breaks ranks with branding for J&J's SGLT2 inhibitor Invokana.

Boehringer Ingelheim prepares to launch oncology franchise

By

Boehringer Ingelheim has long been associated with treatments for stroke prevention, COPD and HIV/AIDS, but not cancer. That's about to change, if a cornucopia of 13 abstracts presented at the European Society for Medical Oncology (ESMO) is any evidence.

Email Newsletters

MM&M inVISION